SAGE Therapeutics Inc: A Promising Q4 2024 Earnings Call
Generated by AI AgentMarcus Lee
Wednesday, Feb 12, 2025 10:59 am ET1min read
BIIB--
SAGE Therapeutics Inc (SAGE) reported its Q4 and full-year 2024 financial results on February 11, 2025, highlighting strong growth in its postpartum depression treatment, ZURZUVAE. The company achieved nearly 2,500 shipments in Q4 2024, a 21% increase from Q3, with over 6,600 prescriptions delivered throughout 2024. ZURZUVAE collaboration revenue was $11.4 million in Q4 2024 and $36.1 million for the year ended December 31, 2024, representing 50% of the net revenues recorded by Biogen.
SAGE Therapeutics maintained a strong financial position with $504 million in cash and equivalents, expecting runway through mid-2027. The company's strategic initiatives, including joint sales force expansions, planned digital marketing campaigns, and increased disease state awareness efforts, contributed to ZURZUVAE's commercial momentum. Greater than 95% of Commercial and Medicaid lives are covered or have a path to coverage, with OBGYNs accounting for almost 80% of all prescriptions. The company saw a strong repeat rate in 2024, with about 60% of targeted HCPs writing repeat prescriptions after prescribing ZURZUVAE, and more than 70% of ZURZUVAE patients receiving the drug as their first new treatment for PPD.
SAGE Therapeutics' Q4 2024 earnings call demonstrated the company's commitment to helping more women with postpartum depression receive treatment with ZURZUVAE, advancing its focused R&D efforts, and creating near and long-term value for Sage and its shareholders. The company's strategic initiatives, strong financial position, and promising Q4 results position SAGE Therapeutics for potential accelerated growth in 2025.
HCP--
SAGE--
SAGE Therapeutics Inc (SAGE) reported its Q4 and full-year 2024 financial results on February 11, 2025, highlighting strong growth in its postpartum depression treatment, ZURZUVAE. The company achieved nearly 2,500 shipments in Q4 2024, a 21% increase from Q3, with over 6,600 prescriptions delivered throughout 2024. ZURZUVAE collaboration revenue was $11.4 million in Q4 2024 and $36.1 million for the year ended December 31, 2024, representing 50% of the net revenues recorded by Biogen.
SAGE Therapeutics maintained a strong financial position with $504 million in cash and equivalents, expecting runway through mid-2027. The company's strategic initiatives, including joint sales force expansions, planned digital marketing campaigns, and increased disease state awareness efforts, contributed to ZURZUVAE's commercial momentum. Greater than 95% of Commercial and Medicaid lives are covered or have a path to coverage, with OBGYNs accounting for almost 80% of all prescriptions. The company saw a strong repeat rate in 2024, with about 60% of targeted HCPs writing repeat prescriptions after prescribing ZURZUVAE, and more than 70% of ZURZUVAE patients receiving the drug as their first new treatment for PPD.
SAGE Therapeutics' Q4 2024 earnings call demonstrated the company's commitment to helping more women with postpartum depression receive treatment with ZURZUVAE, advancing its focused R&D efforts, and creating near and long-term value for Sage and its shareholders. The company's strategic initiatives, strong financial position, and promising Q4 results position SAGE Therapeutics for potential accelerated growth in 2025.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet